1. Relatively effective control of blood glucose, 493 patients with type 2 diabetes (failed dietary control or previously treated) were reported to participate. The baseline mean fasting glucose was about 225mg/dl with a mean hba1c 8.9%. After 4 weeks, patients were randomized to receive rosiglitazone 4mg/d or 8mg/d or placebo for 26 weeks. Compared with placebo, rosiglitazone (4mg/ day or 8mg/ day) significantly reduced empty abdominal glucose by 58mg/dl and 76mg/dl, and HbA1c by 1.2% and 1.5%, respectively.

2. The effect of rosiglitazone monotherapy on postprandial hyperglycemia in patients with type 2 diabetes was studied for 8W. The results showed a significant reduction in postprandial glucose levels in patients with type 2 diabetes, especially in the rosiglitazone 8mg/d group. 

3. The combination with metformin can significantly reduce blood glucose. Chemicalbook works by increasing glucose uptake in skeletal muscle and adipose tissue and metformin in liver sugar output. The results confirm that rosiglitazone combined with metformin is complementary in reducing hyperglycemia. These results indicate that metformin plus rosiglitazone 4mg/d or 8mg/d can significantly reduce fasting blood glucose and HbA1c compared with metformin alone. In addition to blood glucose control, free fatty acids were reduced by 2.6mg/dl and 4.3mg/dl, respectively, from baseline. The main pathogenesis associated with metabolic abnormalities in type 2 diabetes mellitus with sulfonylureas resistance in target tissues, especially skeletal muscle and liver, abnormal decreased glucose uptake and increased hepatic sugar output.